Gilead
Leaked data show Gilead’s remdesivir allows severe COVID-19 patients to be discharged after six days
April 17, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir
The clinical benefit of Gilead’s promising antiviral therapy Remdesivir has been touted in the treatment of severe cases of COVID-19 …
Gilead halts COVID-19 remdesivir trial due to enrolment issues, efficacy of the drug uncertain
April 16, 2020Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir
A clinical trial in China investigating Gilead’s antiviral therapy remdesivir as a potential treatment for COVID-19 has been placed on …
Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute
April 14, 2020Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb
A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s …
Gilead’s promising COVID-19 drug remdesivir shows benefit in 68% of hospitalised patients
April 14, 2020Manufacturing and Production, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir
Gilead has provided an update on its ongoing efforts against the novel coronavirus, revealing data from a cohort analysis of …
Second Genome to help drive development of Gilead therapies in potential $1.5bn deal
April 8, 2020Research and Development Gilead, Second Genome, pharma
Gilead and microbiome science specialist Second Genome have announced they are to partner up to advance a selection of the …
WHO launches “historic” multinational study to investigate most promising COVID-19 therapies
March 30, 2020Research and Development, Sales and Marketing COVID-19, Gilead, coronavirus, pharma, remdesivir
The World Health Organization continues to push forward in the global fight against the novel coronavirus, and has announced the …
Gilead asks FDA to rescind its Orphan Drug status for potential coronavirus treatment following criticism
March 26, 2020Business Services China, Gilead, Wuhan Coronavirus, china coronavirus, coronavirus
Gilead Sciences has submitted a request for the FDA to rescind its offer of Orphan Drug designation for remdesivir in …
COVID-19: Gilead freezes compassionate access to remdesivir due to “overwhelming demand”, BMS and Lilly delay new study launches
March 24, 2020Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, Eli Lilly, Gilead, Roche, cornavirus, pharma
As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and …
FDA greenlights Gilead’s Epclusa in hepatitis C patients over six years old
March 20, 2020Medical Communications, Research and Development Epclusa, Gilead, pharma
Gilead’s Epclusa (sofosbuvir and velpatasvir) has been awarded new marketing approval from the FDA in the treatment of hepatitis C …
Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
First US coronavirus trial launched into Gilead’s remdesivir
February 26, 2020Research and Development FDA, Gilead, US, coronavirus, pharma
The first US clinical trial investigating a treatment for the COVID-19 coronavirus has been launched by the US National Institute …
Sanofi’s head of strategy and business development to retire amid company review
November 25, 2019Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell
One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …
Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome
October 28, 2019Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma
Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
Gilead challenges Government over patents on preventative HIV drug Truvada
August 22, 2019Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents
Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
